Assembling evidence grade
Loading
Independent evidence before payment.
Thymosin beta-4 fragment · also: Thymosin Beta-4 fragment
TB-500 carries an Evidence Grade of C (Medium confidence). The strongest published evidence catalogued is human (other).
Grade C rule: At least one other human study.
The grade reflects the strength of the published evidence, not safety or efficacy. “Confidence” means how settled that grade is given the record — not how likely the compound is to work.
Human-use stop
This compound is investigational, warned or not approved for human use. A seller calling it “research only,” showing testimonials, registering a company or publishing a COA does not create an approved consumer medicine. Seller links below are market-surveillance records, not recommendations.
TB-500 is associated with the thymosin beta-4 protein, studied preclinically for cell migration and tissue repair. Human evidence specific to research-grade TB-500 is limited.
Animal and in-vitro results are shown separately and must never be read as established human outcomes.
In plain terms: there are 2 human studies, but no randomised trial — the strongest test has not been done. Effects seen in smaller studies often do not hold up.
Strongest: randomised or pooled human trials.
none catalogued
Observational, open-label or small human studies.
Logistic regression analysis of environmental and other variables and incidences of tuberculosis in respiratory patients. Scientific reports, 2020.
Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls. Journal of pharmaceutical and biomedical analysis, 2014.
Preclinical animal models — not a human outcome.
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery, 2026.
Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2024.
Cell / tissue studies — not a human outcome.
none catalogued
Proposed mechanism — hypothesis, not evidence of effect.
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Frontiers in aging, 2026.
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.), 2026.
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American journal of sports medicine, 2026.
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026.
Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of chromatography. A, 2012.
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug testing and analysis, 2012.
Elimination of theobromine metabolites in healthy adults. Scandinavian journal of clinical and laboratory investigation, 1996.
Sympathomimetic amines and cardiac arrhythmias. Cardiovascular research, 1990.
On “cited by N”: citation counts (Crossref) reflect how often a paper has been referenced — a measure of academic attention, not of validity, safety, or whether a compound works. They do not affect the Evidence Grade, which is set purely by the strength of the evidence tier.
Most data is animal or in-vitro. Thymosin beta-4 trials do not transfer to unverified TB-500 material. Not approved.
Not an approved medicine in major markets. Sold only as a “research chemical”, with no established safe consumer use, dose or supply standard.
PepCred flags any vendor selling this compound to the public as a consumer-protection concern. Status reflects regulator records; see the regulatory detail below.
Registered studies:
No FDA-approved (US) drug labelling found for this compound. A search of openFDA returned no approved product containing it as an active ingredient.
This reflects US FDA approval only — other regulators (e.g. MHRA, EMA) may differ; see the note below. Absence of an approved label is not, by itself, a safety finding, and a “research use only” label does not establish safety, legality or correct identity.
PepCred note: Not approved for human use.
These unranked records show where the name was detected. For an investigational, warned or unapproved compound, no seller, company registration, review score or COA creates an approved human-use route.
None of these is verified for human use.